使用痕迹:从附件分析中发现药物使用洞察力
Emma L Keller1, Brock Peake1, Bradley S Simpson1
1Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, Australia.
Drug and alcohol review
|January 24, 2026
概括
对药物用品的残留分析显示,经常使用甲基胺和海洛因,通常是组合使用的. 这种方法提供了一种新的客观方法来追踪毒品消费趋势,并为公共卫生战略提供信息.
科学领域:
- 法医化学 法医化学
- 公共卫生 公共卫生
- 毒品使用流行病学
背景情况:
- 对器具的药物残留分析提供了一种新的方法来了解吸毒行为.
- 传统和新型精神活性物质 (NPS) 越来越普遍,需要先进的监测技术.
研究的目的:
- 在南澳大利亚的药物用品中调查常规和新型精神活性物质 (NPS) 的存在和类型.
- 评估药物残留分析作为公共卫生监测工具的可行性和有效性.
主要方法:
- 从南澳大利亚的利物品垃圾箱中收集了300件毒品配件 (注射器,袋子,容器,过器).
- 在甲醇提取后使用液态染色学双重质谱法 (LC-MS/MS) 分析的残留物.
- 通过真实的参考材料确认检测.
主要成果:
- 在61%的器具中检测到甲基胺,在38%的器具中检测到海洛因.
- 大多数物品 (57%) 含有两种或更多种药物,表明使用多种药物.
- 在46个项目中确定了14种不同的新型精神活性物质 (NPS).
结论:
- 药物残留分析是一种可行的,非侵入性和有效的方法,用于近乎实时监测药物消费趋势.
- 检测到的多种药物的高患病率表明,注射毒品的人群中广泛使用多种物质.
- 这种方法补充了现有的方法,加强了减少危害和公共卫生对药物使用模式的反应.
相关概念视频
Therapeutic Drug Monitoring: Drug Analysis Methods
185
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
185
Pharmacokinetics: Drug–Drug Interactions
399
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
399
Bioequivalence of Drugs: Drugs with Multiple Indications
155
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
155
FDA Approved Drugs: Changes to Approved Drugs
248
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
248
Factors Influencing Drug Absorption: Drug Dissolution
1.1K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.1K
Factors Affecting Protein-Drug Binding: Drug-Related Factors
462
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
462


